ReviewInternal and emergency medicine2026
Parvovirus B19 infection as a trigger of acute cholestasis in heterozygous genetic BSEP deficiency: a case report and review of the literature of acute parvovirus B19-related hepatitis.
Review in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bile salt export pump (BSEP) deficiency, also termed progressive familial intrahepatic cholestasis type 2 (PFIC2), is a rare genetic disorder caused by mutations in the ATP-binding cassette, sub-family B member 11 (ABCB11) gene, predisposing to cholestasis and progressive liver damage. Although parvovirus B19 is a recognized but rare cause of acute hepatitis in children, its role in adult liver disease remains uncertain. To expand the knowledge on this topic, we performed a narrative review of published adult cases of B19-associated hepatitis and report the case of a 46-year-old immunocompetent man who developed acute cholestatic hepatitis during B19 infection. The clinical course was not fully attributable to the viral insult alone, prompting further evaluation. Liver histology demonstrated marked loss of BSEP immunoreactivity, and genetic testing identified a heterozygous ABCB11 variant. Despite treatment with ursodeoxycholic acid and cholestyramine, the symptoms persisted, leading to the introduction of the ileal bile acid transporter (IBAT) inhibitor, odevixibat, which resulted in rapid relief of pruritus and near-complete biochemical normalization within 2 months. Our review identified 32 published adult cases of B19-associated hepatitis. Most patients were immunocompetent, with presentations ranging from mild hepatic dysfunction to fulminant liver failure requiring transplantation. In more than half of the patients, predisposing factors such as hematologic disorders or viral co-infections were identified. This review highlights the importance of considering parvovirus B19 infection in the differential diagnosis of acute hepatitis in adults and of investigating potential underlying predisposing factors when the clinical course cannot be fully explained by the viral infection alone.
Indexed as
Identifiers
42496956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.